These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 22828996

  • 1. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
    Wanek T, Kuntner C, Bankstahl JP, Mairinger S, Bankstahl M, Stanek J, Sauberer M, Filip T, Erker T, Müller M, Löscher W, Langer O.
    J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
    [Abstract] [Full Text] [Related]

  • 2. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K, Wanek T, Bankstahl M, Bankstahl JP, Fedrowitz M, Müller M, Löscher W, Kuntner C, Langer O.
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [Abstract] [Full Text] [Related]

  • 3. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
    Biali ME, Auvity S, Cisternino S, Smirnova M, Hacker M, Zeitlinger M, Mairinger S, Tournier N, Bauer M, Langer O.
    Mol Pharm; 2023 Nov 06; 20(11):5877-5887. PubMed ID: 37883694
    [Abstract] [Full Text] [Related]

  • 4. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
    Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, Mitterhauser M, Jäger W, Haslacher H, Müller M, Langer O.
    J Nucl Med; 2013 Aug 06; 54(8):1181-7. PubMed ID: 23833270
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
    Bauer F, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, Stanek J, Mairinger S, Dörner B, Löscher W, Müller M, Erker T, Langer O.
    Bioorg Med Chem; 2010 Aug 01; 18(15):5489-97. PubMed ID: 20621487
    [Abstract] [Full Text] [Related]

  • 6. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
    Bankstahl JP, Bankstahl M, Römermann K, Wanek T, Stanek J, Windhorst AD, Fedrowitz M, Erker T, Müller M, Löscher W, Langer O, Kuntner C.
    Drug Metab Dispos; 2013 Apr 01; 41(4):754-62. PubMed ID: 23305710
    [Abstract] [Full Text] [Related]

  • 7. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
    Mairinger S, Hernández-Lozano I, Filip T, Sauberer M, Löbsch M, Stanek J, Wanek T, Sake JA, Pekar T, Ehrhardt C, Langer O.
    J Control Release; 2022 Sep 01; 349():109-117. PubMed ID: 35798092
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.
    Mairinger S, Langer O, Kuntner C, Wanek T, Bankstahl JP, Bankstahl M, Stanek J, Dörner B, Bauer F, Baumgartner C, Löscher W, Erker T, Müller M.
    Nucl Med Biol; 2010 Jul 01; 37(5):637-44. PubMed ID: 20610168
    [Abstract] [Full Text] [Related]

  • 9. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
    Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD.
    ACS Chem Neurosci; 2011 Feb 16; 2(2):82-9. PubMed ID: 22778859
    [Abstract] [Full Text] [Related]

  • 10. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.
    Bauer F, Wanek T, Mairinger S, Stanek J, Sauberer M, Kuntner C, Parveen Z, Chiba P, Müller M, Langer O, Erker T.
    Eur J Pharmacol; 2012 Dec 05; 696(1-3):18-27. PubMed ID: 23022332
    [Abstract] [Full Text] [Related]

  • 11. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T, Römermann K, Mairinger S, Stanek J, Sauberer M, Filip T, Traxl A, Kuntner C, Pahnke J, Bauer F, Erker T, Löscher W, Müller M, Langer O.
    Mol Pharm; 2015 Sep 08; 12(9):3214-25. PubMed ID: 26202880
    [Abstract] [Full Text] [Related]

  • 12. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, Stundner G, Karch R, Brauner R, Meier M, Ding X, Müller M, Löscher W, Langer O.
    Eur J Nucl Med Mol Imaging; 2010 May 08; 37(5):942-53. PubMed ID: 20016890
    [Abstract] [Full Text] [Related]

  • 13. Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein.
    Dörner B, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, Stanek J, Müllauer J, Bauer F, Mairinger S, Löscher W, Miller DW, Chiba P, Müller M, Erker T, Langer O.
    Bioorg Med Chem; 2011 Apr 01; 19(7):2190-8. PubMed ID: 21419632
    [Abstract] [Full Text] [Related]

  • 14. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K, Helmer R, Löscher W.
    Neuropharmacology; 2015 Jun 01; 93():7-14. PubMed ID: 25645391
    [Abstract] [Full Text] [Related]

  • 15. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
    Liow JS, Zoghbi SS, Hu S, Hall MD, Hines CS, Shetty HU, Araneta MD, Page EM, Pike VW, Kreisl WC, Herscovitch P, Gottesman MM, Theodore WH, Innis RB.
    Neuroimage; 2016 Sep 01; 138():134-140. PubMed ID: 27211474
    [Abstract] [Full Text] [Related]

  • 16. Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [18 F]FPEB in the murine brain.
    Jung KH, Oh SJ, Kang KJ, Han SJ, Nam KR, Park JA, Lee KC, Lee YJ, Choi JY.
    Synapse; 2019 Nov 01; 73(11):e22123. PubMed ID: 31269310
    [Abstract] [Full Text] [Related]

  • 17. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC, Bhatia R, Morse CL, Woock AE, Zoghbi SS, Shetty HU, Pike VW, Innis RB.
    J Nucl Med; 2015 Jan 01; 56(1):82-7. PubMed ID: 25500831
    [Abstract] [Full Text] [Related]

  • 18. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
    Wanek T, Traxl A, Bankstahl JP, Bankstahl M, Sauberer M, Langer O, Kuntner C.
    Nucl Med Biol; 2015 Jul 01; 42(7):585-9. PubMed ID: 25823393
    [Abstract] [Full Text] [Related]

  • 19. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R, Agarwal S, Mittapalli RK, Elmquist WF.
    J Pharmacol Exp Ther; 2013 Apr 01; 345(1):111-24. PubMed ID: 23397054
    [Abstract] [Full Text] [Related]

  • 20. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
    Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, Hall MD.
    Proc Natl Acad Sci U S A; 2013 Dec 17; 110(51):20801-6. PubMed ID: 24297888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.